Explore the best time for ATO to treat PV combined with compound Huangdai tablets

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000004171

Enrollment

Unknown

Registered

2020-12-16

Start date

2021-01-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

1:add AS2O3 after a week of ATO intervention

control group: ATO

3:add AS2O3 3 week after ATO intervention

3:add AS2O3 2 week after ATO intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 14–75 years, Newly diagnosed PV with t(15; 17)(q22; q12); 2. Pre-treatment peripheral blood white blood cell(WBC) count < 10 x 10^9/L; 3. Able to complete the entire treatment process; 4. Signed written informed consent provided by the patient or their family.

Exclusion criteria

Exclusion criteria: 1. Allergy to the drug ingredient or the supplementary material, or having an allergic constitution; 2. Cardiac insufficiency (cardiac contraindications: left-ventricular ejection fraction (L-VEF) 3 times the institutional upper limit of the normal range); 4. Significant arrhythmias, electrocardiogram (EKG) abnormalities (congenital long QT syndrome; history or presence of significant ventricular or atrial tachyarrhythmia; clinically significant resting bradycardia ( 450 ms on screening EKG; right bundle branch block plus left anterior hemiblock, bifascicular block); 5. Combined with other malignant tumors; 6. Pregnant and lactating women; 7. Participants in other drug trials in the last 3 months; 8. Suffering from mental illness or other circumstances which render them unable to complete the treatment plan.

Design outcomes

Primary

Measure	Time frame
PML;RBC count;RCM;HGB;	—

Countries

China

Contacts

Public ContactNa Xu

Southern Hospital

1079844923@qq.com+86 18877316243

Outcome results